Order results by:
| Issue | Title | |
| Vol 5, No 1 (2012) | PHARMACOECONOMIC EVALUATION OF THE PROPHYLAXIS OF POSTSURGICAL INFECTIOUS INFLAMMATORY COMPLICATIONS OF COMBINED ANTIBIOTIC DRUGS AND CORTICOSTEROIDS IN OPHTHALMIC PRACTICE IN RUSSIAN FEDERATION | Abstract similar documents |
| V. G. Serpik, R. I. Yagudina | ||
| Vol 9, No 3 (2016) | HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE | Abstract similar documents |
| A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, Yu. E. Balykina | ||
| "... Objective. To perform health economic evaluation of several antirheumatic drugs in patients ..." | ||
| Vol 10, No 1 (2017) | EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... aspects) drug for the treatment of widespread progressing differentiated thyroid cancer (DTC) refractory ..." | ||
| Vol 10, No 2 (2017) | THE USE OF MULTI-CRITERIAL DECISION ANALYSIS (MCDA) FOR ESTIMATING THE THERAPEUTIC VALUE OF INNOVATIVE DRUGS | Abstract similar documents |
| V. K. Fedyaeva, V. V. Omelyanovskiy, N. Z. Musina, G. R. Khachatryan, O. I. Ivakhnenko | ||
| Vol 13, No 3 (2020) | Evaluation of the antitumor drugs therapeutic value using the method of multicriterial analysis of decision-making | Abstract similar documents |
| V. A. Lemeshko, N. Z. Musina, V. V. Omelyanovskiy | ||
| "... Aim. Development of a tool for the evaluation of the therapeutic value of anticancer drugs based ..." | ||
| Vol 13, No 4 (2020) | Pharmacoeconomic feasibility of using the drug Hemangiol (propranolol, oral solution) in the treatment of proliferating infantile hemangioma requiring systemic therapy | Abstract similar documents |
| I. N. Dyakov, S. R. Varfolomeеva | ||
| Vol 10, No 1 (2017) | PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS | Abstract similar documents |
| A. S. Kolbin, I. A. Vilum, М. A. Proskurin, Yu. E. Balykina | ||
| "... that the introduction of brentuximab vetodin in the List of vital and essential drugs and the Program of state ..." | ||
| Vol 11, No 3 (2018) | The concept of multi-criteria analysis of decision-making in the current system of health technology assessment in Russia | Abstract similar documents |
| V. V. Omelyanovsky, V. K. Fedyaeva, N. Z. Musina | ||
| Vol 12, No 1 (2019) | Evaluation of the clinical efficacy of anti-asthma pharmacotherapy in children using the software package based on the Fishburn method | Abstract similar documents |
| O. V. Zhukova, I. V. Nikiforova | ||
| "... for the distribution of drugs by levels of clinical efficacy” is presented. Conclusion. It has been shown ..." | ||
| Vol 13, No 3 (2020) | The use of various genetically engineered biological drugs and selective immunosuppressants within the current provider-payment model of russian diagnosis-related groups | Abstract similar documents |
| E. V. Derkach, E. A. Pyadushkina, M. V. Avxentyeva, T. V. Boyarskaya, E. E. Yagnenkova, A. S. Mokrova, M. M. Maryanyan | ||
| "... of the range of genetically-engineered biological drugs (GEBD) and the development of new indications ..." | ||
| Vol 12, No 4 (2019) | Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis | Abstract similar documents |
| I. V. Sarvilina, A. N. Galustyan, A. K. Hadzhidis, I. S. Sardaryan, N. V. Lavrov, O. A. Gromova, Yu. S. Prokofieva | ||
| "... Aim: to conduct a comparative clinical and economic analysis of using three SYSADOA drugs ..." | ||
| Vol 7, No 4 (2014) | ANALYSIS OF GOVERNMENT PROCUREMENTS OF MEDICINES APPLIED IN RARE DISEASES THERAPY | Abstract similar documents |
| D. V. Fedyaev, V. K. Fedyaeva, V. V. Omelyanovsky | ||
| "... the article presents the results of analysis of the state procurement of the drugs for rare ..." | ||
| Vol 10, No 4 (2017) | IMPROVEMENT OF PRICE REGULATION FOR INNOVATIVE MEDICINES COVERED BY THE NATIONAL BUDGET | Abstract similar documents |
| V. A. Lemeshko, N. Z. Musina, V. K. Fedyaeva | ||
| "... The current approaches to the drug pricing commonly used worldwide allow for incorporating ..." | ||
| Vol 6, No 4 (2013) | Pharmacoepidemiology of stroke treatment in different hospitals | Abstract similar documents |
| N. V. Mikheeva, O. V. Reshetko, L. G. Ryzhenkova | ||
| "... out the rational use of drugs and to identify ways to optimize the consumption of drugs. The results ..." | ||
| Vol 9, No 2 (2016) | PHARMACOECONOMIC ANALYSIS OF THE THERAPY OF СHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS IN HOSPITAL CONDITIONS | Abstract similar documents |
| E. E. Vidyakina, S. V. Malchikova | ||
| "... Objective. To determine the priority used to vital drugs in сhronic obstructive pulmonary disease ..." | ||
| Vol 8, No 4 (2015) | ABC-, VEN- AND FREQUENCY ANALYSIS OF TREATMENT OF ATRIAL FIBRILLATION IN OUTCOME PATIENTS | Abstract similar documents |
| A. N. Korobeynikova, S. V. Malchikova | ||
| "... studies allow to evaluate the quality of drug therapy for atrial fibrillation, find rational drug usage ..." | ||
| Vol 5, No 1 (2012) | PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION | Abstract similar documents |
| R. Yagudina, A. Kulikov, B. Misikova | ||
| "... with Revlimid in Russia was conducted. It has shown, that application of lenalidomide as a drug of choice ..." | ||
| Vol 7, No 1 (2014) | CLINICAL AND ECONOMIC ANALYSIS IN ASSESSMENT OF HEALTH CARE TECHNOLOGIES IN HEALTH CARE INSTITUTIONS | Abstract similar documents |
| I. B. Gaykovaya, A. T. Burbello, A. I. Ermakov, A. S. Fedorenko, T. V. Vavilova, M. V. Komok | ||
| "... the introduction of new methods of clinical and laboratory diagnostics to assess the efficacy of drug therapy ..." | ||
| Vol 9, No 4 (2016) | PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION | Abstract similar documents |
| D. S. Kaskaeva, M. M. Petrova, O. V. Zimnitskaya | ||
| "... Objective. Pharmacoeconomic analysis of the use of combinations of antihypertensive drugs were ..." | ||
| Vol 11, No 3 (2018) | Use of medications in children hospitalized with community-acquired pneumonia | Abstract similar documents |
| D. D. Siukaeva, I. A. Narkevich, V. N. Timchenko, O. D. Nemyatyh, N. A. Maslova | ||
| "... respiratory tract prevailed (32.20%). As for the medications, the category J drugs “Antimicrobials of systemic ..." | ||
| Vol 13, No 4 (2020) | Peptides contained in the composition of Laennec that contribute to the treatment of hyperferritinemia and iron overload disorders | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin, V. A. Maksimov, A. G. Chuchalin, V. G. Zgoda, А. N. Gromov, O. V. Tikhonova | ||
| "... organ diseases. Polypeptide-containing drug Laennec contributes to the elimination of excessive iron ..." | ||
| Vol 8, No 3 (2015) | COMPARATIVE PHARMACOECONOMIC STUDY OF VITAMIN-MINERAL COMPLEXES FOR REHABILITATION DURING THE PERIOD OF INCREASED NEEDS FOR MICRONUTRIENTS | Abstract similar documents |
| A. Yu. Belinskaya, I. Yu. Torshin, T. R. Grishina, O. A. Gromova | ||
| "... data VEC to 127 regions of Russia formulated price categories of drugs and the analysis of available ..." | ||
| Vol 9, No 1 (2016) | COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA | Abstract similar documents |
| G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy | ||
| "... part we calculated ICER for BV vs standard treatment based on drugs costs only and compared ..." | ||
| Vol 7, No 1 (2014) | ROLE OF RANDOMIZED TRIALS IN PHARMACOEPIDEMIOLOGY | Abstract similar documents |
| T. L. Galankin, A. S. Kolbin | ||
| "... in post-marketing drug research by the example of large simple trials. ..." | ||
| Vol 10, No 3 (2017) | Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients | Abstract similar documents |
| N. K. Mazina, P. V. Mazin | ||
| "... analysis of patient management was conducted for each of the three drugs. The direct costs included ..." | ||
| Vol 7, No 2 (2014) | THE ANALYSIS OF THE LIPETSK PHARMACEUTICAL MARKET OF NASAL GLUCOCORTICOSTEROID | Abstract similar documents |
| K. V. Danilova, I. M. Razdorskaya | ||
| "... in the present paper we have studied a group of pharmaceutical drugs used in the treatment ..." | ||
| Vol 9, No 2 (2016) | BUDGET IMPACT ANALYSIS OF PERAMPANEL FOR ADJUNCTIVE TREATMENT IN EPILEPSY PATIENTS 12 YEARS OF AGE AND OLDER FOR PARTIAL ONSET SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION AND PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN THE RUSSIAN FEDERATION | Abstract similar documents |
| V. R. Mkrtchyan, A. M. Sergeev, K. I. Pochigaeva, I. A. Shpak | ||
| "... costs included drugs and medical resources (hospitalization, emergency care costs, visits to physician ..." | ||
| Vol 11, No 4 (2018) | Costs of pharmacotherapy in pediatric patients with community-acquired pneumonia: mathematical and statistical analysis | Abstract similar documents |
| I. A. Narkevich, O. D. Nemyatyh, D. D. Siukaeva, I. V. Pavlushkov, D. O. Ivanov, Ya. V. Panyutina | ||
| "... , duration of hospital stay, cost of therapy, number of prescribed drugs, number of affected lung segments ..." | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC EVALUATION OF TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS ON DIALYSIS WITH CINACALCET | Abstract similar documents |
| R. I. Yagudina, V. G. Serpik | ||
| "... Abstract: the pharmacoeconomic study compared the standard drug therapy (vitamin D ..." | ||
| Vol 9, No 1 (2016) | PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... ) new practice where lenvatinib is used in 6.25% patients. Costs of drugs, visits to oncologist ..." | ||
| Vol 9, No 2 (2016) | EVALUATION OF RATIONALITY OF EXPENSES ON TREATMENT OF SEVERE COMMUNITY-ACQUIRES PNEUMONIA IN MULTI-PROFILE HOSPITAL | Abstract similar documents |
| I. V. Demko, N. V. Gordeeva, E. N. Bochanova, N. I. Golovina, A. Yu. Kraposhina, I. A. Soloveva, E. A. Sobko, T. V. Gaygolnik, S. V. Chubarova | ||
| "... drug treatment and identification of frequency of the separate medicinal preparations. We have data ..." | ||
| Vol 11, No 4 (2018) | Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer | Abstract similar documents |
| N. A. Avxentyev, A. S. Makarov, M. Yu. Frolov | ||
| "... Introduction. A number of drugs, which improve overall survival and quality of patients’ life ..." | ||
| Vol 13, No 2 (2020) | Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation | Abstract similar documents |
| S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova | ||
| "... ) in comparison with other medications, included in the Vital and Essential Drugs List (VEDL), for the maintenance ..." | ||
| Vol 5, No 1 (2012) | PHARMACOECONOMICS AS A NEW INSTRUMENT OF PHARMACEUTICAL MARKETING | Abstract similar documents |
| M. V. Protsenko, N. I. Koroleva | ||
| "... of evidence for drugs recently introduced into clinical practice. Utilization of pharmacoeconomic analysis ..." | ||
| Vol 8, No 4 (2015) | CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS | Abstract similar documents |
| E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva | ||
| "... between the drugs in terms of clinical efficacy and safety and this hypothesis is grounded on the results ..." | ||
| Vol 9, No 2 (2016) | PHARMACO-ECONOMIC ANALYSIS OF COST IN TERMS OF MAINTENANCE OF PREFERENTIAL MEDICINES PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ON THE TERRITORY OF KRASNOYARSK REGION | Abstract similar documents |
| T. V. Gaygolnik, I. V. Demko, E. N. Bochanova, A. Yu. Kraposhina, N. V. Gordeeva, I. A. Soloveva | ||
| "... .7%) and Salmeterol/ Fluticasonum (11%). The nomenclature of International unlicensed name of the drugs which ..." | ||
| Vol 10, No 2 (2017) | COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD | Abstract similar documents |
| E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov, N. L. Bondarenko, A. V. Karaulov | ||
| "... The recently introduced novel drug combinations for the treatment of COPD are based on long-acting ..." | ||
| Vol 10, No 2 (2017) | PHARMACOECONOMIC ASPECTS OF NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY | Abstract similar documents |
| A. V. Rudakova, S. A. Protsenko, I. A. Koroleva | ||
| "... on pricing entered with no discounts for a period of 1-5 years. The costs of the immunotherapeutic drugs were ..." | ||
| Vol 10, No 3 (2017) | ABC-analysis of pharmacotherapy in children hospitalized with bronchial asthma exacerbations | Abstract similar documents |
| O. V. Zhukova, S. V. Kononova | ||
| "... . In relation to the field of medicinal use, the analyzed drugs were distributed into three classes (A, B and C ..." | ||
| Vol 13, No 4 (2020) | Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm | Abstract similar documents |
| M. Yu. Frolov, A. S. Salasyuk, V. A. Rogov | ||
| "... )-6 drugs: tocilizumab, olokizumab, and levilimab in patients with severe COVID-19 and cytokine storm ..." | ||
| Vol 10, No 2 (2017) | COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD | Abstract similar documents |
| E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov | ||
| "... ) was used as the main criterion of effectiveness. Direct medical costs of drug therapy, and the costs ..." | ||
| Vol 6, No 2 (2013) | FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS | Abstract similar documents |
| A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure | ||
| "... . Demographic, biochemical etc. patient parameters were used as input parameters. Glucose lowering drug’s ..." | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH FIX COMBINATION OF CARBONIC ANHYDRASE INHIBITORS AND BETABLOCKERS | Abstract similar documents |
| M. V. Protsenko | ||
| "... and can be claimed dominant. Futhermore Azarga in comparison with Dorzopt plus is cost-effective drug ..." | ||
| Vol 10, No 1 (2017) | CLINICAL AND ECONOMIC EVALUATION OF ERIBULIN EFFECTIVENESS IN SOFT TISSUE SARCOMA: RESULTS OF META-ANALYSIS | Abstract similar documents |
| P. V. Мazin, I. V. Sheshunov, N. K. Mazina, E. M. Markova | ||
| "... Innovative drugs eribulin and trabectedin are effective in the treatment of soft tissue sarcomas ..." | ||
| Vol 10, No 1 (2017) | BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS | Abstract similar documents |
| E. A. Pyadushkina | ||
| "... of drugs from the list of vital and essential drugs (VED), the size of the maximal wholesale mark-ups ..." | ||
| Vol 10, No 1 (2017) | THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN THE EVALUATION OF MEDICAL TECHNOLOGIES | Abstract similar documents |
| N. Z. Musina, V. K. Fedyaeva | ||
| "... of QALY as a measure of drug effectiveness is not yet possible because of the lack of standardized ..." | ||
| Vol 8, No 2 (2015) | ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA | Abstract similar documents |
| Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov | ||
| "... the schemes of antiretroviral therapy as compared to the schemes on the basis of drugs from the group ..." | ||
| Vol 12, No 3 (2019) | Comorbidity in elderly patients with atrial fibrillation affects the “cost of illness” | Abstract similar documents |
| S. V. Malchikova , N. S. Maksimchuk-Kolobova, M. V. Kazakovtseva | ||
| "... medications. However, patients with high comorbidity still need more vital drugs, as the cost of treatment ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis | Abstract similar documents |
| R. I. Yagudina, M. M. Murashko | ||
| "... and Sterofundin drugs were compared during the analysis. A cost analysis, cost-effectiveness analysis, budget ..." | ||
| 51 - 100 of 123 Items | << < 1 2 3 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
